Clinical trials
Thrombocytopenia clinical trials
Below are recruiting thrombocytopenia clinical trials, each written for real people, not researchers. We’re tracking 135 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07442513RecruitingPhase 3
Preventing Bleeding in Stem Cell Transplant
This trial tests if a medication called etamsylate can help prevent bleeding in patients getting a stem cell transplant. If your platelet count drops very low after transplant, this drug may reduce your risk of bleeding.
Hangzhou, ZhejiangAges 18–70 - NCT07394153RecruitingPhase 2
Testing pacritinib for myelofibrosis patients with low platelets
This trial tests if pacritinib, a JAK inhibitor, can help people with myelofibrosis who also have low platelet counts. It may be an option for those who haven't had JAK inhibitor therapy before or who didn't respond to a previous one.
Barcelona, BarcelonaAges 18 years+ - NCT04890041Recruiting
Testing TPO medicines for immune low platelets in teens
This trial studies whether “TPO” medicines (like eltrombopag or similar drugs) help people age 14 and older with primary immune thrombocytopenia (ITP) who did not respond well to first treatments. It may help raise platelet counts and reduce bleeding, especially when prior therapy hasn’t worked.
Tianjin, Tianjin MunicipalityAges 14 years+ - NCT07358910Recruiting
Tracking infectious diseases in communities
This study looks at how infections spread in villages in Cambodia. If you live in a participating village, you might help us understand and prevent disease outbreaks.
Phnom Penh, Phnom PenhAges 2–75 - NCT07315087RecruitingPhase 1
CAR T-cell therapy for autoimmune diseases
This trial tests a special type of cell therapy (CAR T-cells) that targets two markers on immune cells, CD19 and BCMA, to calm overactive immune systems in people with certain autoimmune diseases. It's for those whose disease has not been controlled by standard treatments.
TianjinAges 18 years+ - NCT06245746RecruitingPhase 1
Exosomes for low blood counts after chemo in leukemia
This trial tests whether umbilical cord mesenchymal stem cell exosomes can help restore blood cell counts after chemotherapy in adults with acute myeloid leukemia who are in remission. It aims to reduce the risk of infection and bleeding while waiting for bone marrow recovery.
Wuhan, HubeiAges 18–60 - NCT04005638Recruiting
Biobank for people with autoimmune blood cell disorders
This study collects and stores biological samples (a “biobank”) from people with autoimmune cytopenia, so researchers can learn more about the condition. If you qualify, your samples may help future studies and improve care, and it’s based on voluntary consent.
PessacAges 18 years+ - NCT07257809RecruitingPhase 2
Herombopag for low platelets from T-DM1 in breast cancer
This trial tests if herombopag can help raise platelet counts in breast cancer patients who have low platelets caused by the drug T-DM1 after prior anti-HER2 therapy. If it works, it may allow you to continue T-DM1 without delays or dose reductions.
Guangzhou, GuangdongAges 18–75 - NCT07230067Recruiting
Sepsis with low platelets: platelet transfusion study
This study looks at whether platelet transfusions help patients with sepsis and very low platelet counts recover better. If you or your loved one had sepsis, a low platelet count, and were in the ICU for at least two days, this trial may be relevant.
Guangzhou, GuangdongAges 18 years+ - NCT07175493RecruitingPhase 1/Phase 2
CM336 for relapsed or refractory autoimmune cytopenia
This study tests a new drug called CM336 for people whose immune system mistakenly attacks their own blood cells (autoimmune cytopenia) and hasn't been controlled by other treatments. The goal is to see if CM336 can safely help improve blood cell counts.
Zhengzhou, HenanAges 18 years+ - NCT07174843RecruitingEarly Phase 1
CAR-T cell therapy for autoimmune diseases
This study tests a new type of cell therapy called CAR-T cells that target three proteins (CD19, CD22, BCMA) to treat people with autoimmune diseases that have not responded to standard treatments. The goal is to see if it can reset the immune system and reduce disease activity.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT07172100Enrolling by invitationPhase 2
Papaya Leaf Extract for Kids with Dengue and Low Platelets
This trial tests if papaya leaf extract can help raise low platelet counts in young children with dengue fever. It may offer a natural way to reduce the risk of bleeding.
KarachiAges 2–12 - NCT07133659RecruitingPhase 4
New starting dose of avatrombopag for immune thrombocytopenia
This study tests a modified starting dose of avatrombopag, a medication that helps raise platelet counts, in adults with immune thrombocytopenia (ITP) who have not responded well to first-line steroid treatments. The goal is to see if this new dosing is effective and safe.
BaghdadAges 18 years+ - NCT07104565RecruitingPhase 2
Tafasitamab for autoimmune blood cell disorders
This study tests a new drug, tafasitamab, for people with immune thrombocytopenia (ITP) or warm autoimmune hemolytic anemia (wAIHA) that has not been controlled well by other treatments. The goal is to see if it is safe and can help manage these blood cell disorders.
Glendale, ArizonaAges 18 years+ - NCT07093606Recruiting
Eltrombopag and liver function in ITP patients
This study looks at how the drug eltrombopag affects the liver in people with primary ITP (immune thrombocytopenic purpura), a condition where the immune system destroys platelets. It aims to check if liver problems develop during treatment and who might be at higher risk.
SohagAges 18–75 - NCT07083960RecruitingPhase 1
Study of OM336 for low blood cell counts caused by immune system
This trial tests a new drug called OM336 for people whose immune system is attacking their own blood cells, causing low counts. It is for those who have already tried at least one treatment that did not work well or stopped working.
Duarte, CaliforniaAges 18–75 - NCT06349577Recruiting
Bypass machine settings to protect kidneys during heart surgery
This study tests whether a special way of running the heart-lung bypass machine during planned heart surgery can help protect your kidneys and reduce the risk of kidney injury after the operation.
Aurora, ColoradoAges 18–85 - NCT07068126Recruiting
New treatment for kids with lasting ITP
This trial tests a new approach for children ages 1 to 10 who have had ITP for 3–12 months. It aims to find a better way to manage the condition and improve platelet counts.
AsyutAges 1–10 - NCT07072247RecruitingPhase 1
RN1201 injection for hard-to-treat antibody-mediated blood disorders
This trial tests a new injection called RN1201 for people with antibody-mediated diseases, specifically two types of blood disorders: platelet transfusion refractoriness (PTR) and immune thrombocytopenia (ITP) that haven't responded to standard treatments. The goal is to see if RN1201 can help control these conditions.
Suzhou, JiangsuAges 16–65 - NCT07048249RecruitingEarly Phase 1
Romiplostim to prevent low platelets in Ewing sarcoma
This trial tests a platelet-boosting medicine called romiplostim to prevent dangerously low platelet counts caused by chemotherapy in children with newly diagnosed Ewing sarcoma. It is designed for patients who do not have cancer spread to the bone marrow and have not taken similar platelet drugs before.
Phoenix, ArizonaAges 1 year+ - NCT06948318RecruitingPhase 3
Follow-up study of mezagitamab for chronic ITP
This study follows up with adults who completed a previous mezagitamab trial for chronic immune thrombocytopenia (ITP). It monitors long-term safety and effectiveness of the treatment.
Hot Springs, ArkansasAges 18 years+ - NCT06941129RecruitingPhase 1
CAR T-cell therapy for resistant autoimmune diseases
This trial tests a new type of immune therapy called CAR T-cells that target two markers on your B cells (CD19 and BCMA). It is for people with certain autoimmune diseases that have not improved or have come back after standard treatments. The goal is to see if this therapy can help control the disease.
TianjinAges 18 years+ - NCT06888960RecruitingEarly Phase 1
Testing CC312 for people with autoimmune diseases
This early-phase study tests a new drug called CC312 in patients with certain autoimmune diseases like lupus, myositis, scleroderma, rheumatoid arthritis, immune thrombocytopenia, or autoimmune hemolytic anemia. The goal is to see if it's safe and how the body handles it.
Tianjin, ChinaAges 18 years+ - NCT05152238Recruiting
ITP registry and optional blood sample collection study
This study helps doctors better understand immune thrombocytopenia (ITP) by collecting basic patient information and, if you agree, storing blood samples. It may help future care decisions and research for people with ITP.
AachenAges 18 years+
Hear when a new Thrombocytopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for thrombocytopenia?
- Yes. Clin2 currently lists 135 recruiting thrombocytopenia studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a thrombocytopenia trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a thrombocytopenia trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.